Patents Assigned to MORS
  • Traffic Sign Mountable Light Panels
    Publication number: 20180033259
    Abstract: A system for detecting a vehicle traveling a designated direction of travel on a roadway includes a sign having a front surface and a back surface. The sign may include a sign boundary marker that is different in color than a color of the front surface. One or more light panels such as an LED light panel is affixed to the sign such as to its front surface. The light emitting elements may lie below a top plane of the light panel. A color of a top surface of the light panel matches a color on the front surface of the sign over which the light panel is placed. A vehicle motion detector or proximity detector is oriented in a direction and has a detection zone for detecting moving vehicles in proximity to the sign. The detector illuminates the lights of the light panel after detecting a moving vehicle in proximity to the sign.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Applicant: MOR Manufacturing Corporation
    Inventors: Ken Cummings, John Ragan, Chris Beaty
  • Compositions and methods for treatment of retinal degenerative diseases
    Patent number: 9878021
    Abstract: This disclosure relates to compositions for use in treatment of a retinal degenerative disease, such as age related macular degeneration. The described compositions include agents for activating p38 and/or JNK signaling through the activation of TAK1 in the retinal pigment epithelium of a subject diagnosed with the disease. Methods of treatment of a retinal degenerative disease using the described compositions are also provided.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: January 30, 2018
    Assignee: MOR RESEARCH APPLICATIONS LTD.
    Inventors: Ayala Pollack, Zeev Dvashi
  • Apparatus and method for diagnosing obstructive sleep apnea
    Patent number: 9844336
    Abstract: An embodiment of the invention provides a method of diagnosing obstructive sleep apnea, the method comprising: acquiring a sleep sound signal comprising sounds made by a person during sleep; detecting a plurality of snore sounds in the sleep sound signal; determining a set of mel-frequency cepstral coefficients for each of the snore sounds; determining a characterizing feature for the sleep sound signal responsive to a sum of the variances of the cepstral coefficients; and using the characterizing feature to diagnose obstructive sleep apnea in the person.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: December 19, 2017
    Assignees: Ben Gurion University of the Negev Research and Development Authority, Mor Research Applications Ltd.
    Inventors: Yaniv Zigel, Ariel Tarasiuk, Nir Ben Israel
  • Methods and compositions for targeted two-dimensional western blot analysis for early cancer detection and cancer diagnosis up to ten years in advance of clinical symptoms of malignant disease
    Patent number: 9804165
    Abstract: The present invention includes methods for detecting benign to malignant transformation of a cancer in a subject, comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretically separated ENOX2 transcript variants with an ENOX2 electron donor; and detecting the presence of the one or more activated ENOX2 transcript variants using a pan-ENOX2 detectable binding reagent, wherein the presence of one or more activated ENOX2 transcript variants in the sample is indicative of the malignant transformation of the cancer, whereby a 10 to 100 fold increase in detection sensitivity is obtained for the one or more activated ENOX2 transcript variants when compared to an equivalent non-activated ENOX2 transcript variant.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 31, 2017
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventor: D. James Morre
  • Methods for single chain variable region ENOX2 antibodies for cancer detection and diagnosis
    Patent number: 9804166
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 31, 2017
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • PROGNOSTIC METHODS AND SYSTEMS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA
    Publication number: 20170268070
    Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.
    Type: Application
    Filed: July 30, 2015
    Publication date: September 21, 2017
    Applicant: MOR RESEARCH APPLICATIONS LTD.
    Inventors: Smadar AVIGAD, Isaac YANIV, Keren SHICHRUR
  • COMPOSITIONS AND METHODS FOR TREATMENT OF RETINAL DEGENERATIVE DISEASES
    Publication number: 20170266146
    Abstract: This disclosure relates to compositions for use in treatment of Alzheimer's Disease, and/or a ocular and retinal degenerative disease, such as age related macular degeneration. The described compositions include effective amounts of LLMe, the hydrobromide form thereof, or functional derivatives thereof. Methods of treatment of a retinal degenerative disease of Alzheimer's Disease using the described compositions are also provided.
    Type: Application
    Filed: December 3, 2015
    Publication date: September 21, 2017
    Applicant: MOR RESEARCH APPLICATIONS LTD.
    Inventors: Zeev DVASHI, Ayala POLLACK
  • Compositions and methods for prognosis of gastric cancer
    Patent number: 9765334
    Abstract: Described herein are compositions and methods for survival prediction in gastric cancer patients after surgical operation. The compositions are microRNA molecules associated with the prognosis of gastric cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: September 19, 2017
    Assignees: Rosetta Genomics, Ltd., Mor Research Applications
    Inventors: Moshe Hoshen, Raruch Brenner
  • EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) PEPTIDES AND BINDING ANTIBODIES
    Publication number: 20170247422
    Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
    Type: Application
    Filed: May 16, 2017
    Publication date: August 31, 2017
    Applicants: MOR - RESEARCH APPLICATIONS LTD., RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
    Inventors: Michal A. RAHAT, Nitza LAHAT, Miriam WALTER, Haim BITTERMAN
  • Methods and compositions for single chain variable region ENOX2 antibodies for cancer detection and diagnosis
    Patent number: 9739782
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 22, 2017
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Methods and compositions for determining heart failure or a risk of heart failure
    Patent number: 9631236
    Abstract: The present invention is based in part on the discovery of a panel of miRs whose levels are increased or decreased in the circulation of chronic systolic HF patients. Accordingly, an extensive panel of miRs was screened in the sera of stable chronic systolic HF patients and the results were compared to an age, gender and ethnically matched control group.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: April 25, 2017
    Assignees: Rosetta Genomics Ltd., MOR Research Applications Ltd.
    Inventors: Yaron Goren, Ofer Amir
  • Wrong Way Alert
    Publication number: 20170103656
    Abstract: Methods and systems are described for providing increased success in detecting a motor vehicle traveling against a designated direction of travel in a roadway. Multiple signals among various system constituents are checked against each other to ensure the lack of a false wrong way indication otherwise possible by use of a single detector. An alert is provided to the wrong way motor vehicle operator and other vehicle operators in the vicinity of detection. The alert promotes the potential for avoiding head-on collisions between vehicles and for saving lives. A long-range or cellular communication may be broadcast to further provide an alert of a wrong way event and to dispatch emergency personnel to the vicinity.
    Type: Application
    Filed: October 6, 2016
    Publication date: April 13, 2017
    Applicant: MOR Manufacturing Corporation
    Inventors: Kenneth R. Cummings, II, John Lloyd Ragan, Chris Beaty
  • Methods and compositions for targeted two-dimensional western blot analysis for early cancer detection and cancer diagnosis up to ten years in advance of clinical symptoms of malignant disease
    Patent number: 9612243
    Abstract: The present invention includes methods for detecting benign to malignant transformation of a cancer in a subject, comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretically separated ENOX2 transcript variants with an ENOX2 electron donor; and detecting the presence of the one or more activated ENOX2 transcript variants using a pan-ENOX2 detectable binding reagent, wherein the presence of one or more activated ENOX2 transcript variants in the sample is indicative of the malignant transformation of the cancer, whereby a 10 to 100 fold increase in detection sensitivity is obtained for the one or more activated ENOX2 transcript variants when compared to an equivalent non-activated ENOX2 transcript variant.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: April 4, 2017
    Assignee: MOR-NUCO ENTERPRISES, INC.
    Inventor: D. James Morre
  • Compositions and methods for prognosis of ovarian cancer
    Patent number: 9540695
    Abstract: Described herein are compositions and methods for the prediction of the prognosis of ovarian cancer subjects. The present invention further provides methods for distinguishing between histological subtypes of ovarian cancer tumors, and also methods and compositions for the treatment or prevention of ovarian cancer. Specifically the invention relates to microRNA molecules associated with said methods and compositions, as well as various nucleic acid molecules relating thereto or derived therefrom.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: January 10, 2017
    Assignees: Rosetta Genomics Ltd., MOR Research Applications
    Inventors: Moshe Hosen, Gila Lithwick Yanai, Ram Eitan
  • Fertility preservation device
    Patent number: 9532901
    Abstract: The invention relates to ovary apparatus for regulating the temperature of the ovary; and shielding it from radiation. The main function of the device is to preserve fertility of women treated with chemotherapy by lowering the ovary temperature while the toxic medications circulate in the patients' blood. The current invention utilizes shielding of the ovary to protect it from radiation, and temperature decrease to further limit the toxic effect of radiation.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: January 3, 2017
    Assignee: Mor Research Applications Ltd.
    Inventor: Nicola Nasser
  • Methods and compositions for single chain variable region ENOX2 antibodies for cancer detection and diagnosis
    Patent number: 9459256
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: October 4, 2016
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D James Morrè, Brandon Eugene Hostetler, James Jinpal Kim
  • SOLUBLE CTLA-4 MOLECULES AND DERIVATIVES THEREOF FOR TREATMENT OF MINIMAL CHANGE DISEASE
    Publication number: 20160271218
    Abstract: This disclosure relates to compositions and methods for treatment of minimal change disease. The compositions include soluble CTLA-4 molecules, and derivatives thereof, including belatacept and belatacept-like molecules that have been conjugated to a human immunoglobulin constant domain fragment.
    Type: Application
    Filed: June 26, 2014
    Publication date: September 22, 2016
    Applicant: Mor Research Applications Ltd.
    Inventor: Alexander BIRO
  • Device for placement in the tricuspid annulus
    Patent number: 9445893
    Abstract: A device (200) for implantation in or near an annulus of a tricuspid valve comprising at least one blood flow control element (202) adapted to capture a volume of blood therein. Optionally or alternatively, the blood flow control element is adapted to allow at least some volume of blood (406) to regurgitate through the annulus during at least some part of systole. Optionally or alternatively, the device comprises a relatively rigid annulus with an arc length of less than 300 degrees. Optionally or alternatively, the relatively rigid annulus comprises a plurality of tissue fixation elements positioned along no more than 300 degrees of a circumference of the annulus, for example to avoid damaging conduction pathways between an atria and a chamber.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: September 20, 2016
    Assignee: Mor Research Applications Ltd.
    Inventor: Mordehay Vaturi
  • PROGNOSTIC METHODS, COMPOSITIONS AND KITS FOR PREDICTION OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) RELAPSE
    Publication number: 20160222464
    Abstract: The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL, and appropriate associated treatments thereof.
    Type: Application
    Filed: February 3, 2016
    Publication date: August 4, 2016
    Applicant: Mor Research Applications Ltd.
    Inventors: Smadar Avigad, Isaac Yaniv
  • Method and system for analyzing craniofacial complex images
    Patent number: 9402565
    Abstract: In a method of analysis, a target image is registered to define a plurality of keypoints arranged in sets corresponding to polygons or linear segments in the target image. A database of registered and annotated images is accessed and a polygon-wise comparison between the target image and each database image is employed. The comparison is used for projecting annotated locations from the database images into the target image.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: August 2, 2016
    Assignees: Mor Research Applications Ltd., Ramot at Tel-Aviv University Ltd.
    Inventors: Yehuda Finkelstein, Lior Wolf